Background and Purpose-Although obesity is an established risk factor for the occurrence of a primary stroke, little is known about the impact of baseline obesity on recurrent vascular risk among patients with recently symptomatic cerebrovascular disease. We evaluated the association of obesity with future vascular risk in patients with a recent history of stroke. Methods-We analyzed the database of a multicenter trial involving 20 332 patients with recent ischemic stroke followed for 2.5 years. Subjects were divided into 3 groups according to recognized body mass index categories representing lean, overweight, and obese. Primary outcome was time to first recurrent stroke and secondary outcome time to stroke, myocardial infarction, or vascular death. The independent association of obesity with outcome was assessed by controlling for other known risk factors. Results-Of 20 246 eligible subjects, 4805 (24%) were obese. After adjusting for confounders, compared with the lean group, being overweight (hazard ratio, 0.95; 95% CI, 0.85-1.06) or obese (hazard ratio, 0.95; 95% CI, 0.83-1.08) was not associated with increased recurrent stroke risk, but being overweight (hazard ratio, 0.84; 95% CI, 0.77-0.92) or obese (hazard ratio, 0.86; 95% CI, 0.77-0.96) was associated with lower risk of a major vascular event. Conclusions-Obesity is not related to recurrent stroke risk, but obese patients with stroke are at lower overall vascular risk than their leaner counterparts, supporting the widely held notion of the existence of a cardiovascular "obesity paradox." (Stroke. 2011;42:3397-3402.)
O besity, a growing public health problem, 1 is associated with chronic inflammation, thrombosis, oxidative damage as well as metabolic derangements, [2] [3] [4] and is increasingly being recognized as an important risk factor for primary stroke in general populations. [5] [6] [7] [8] The increased risk of obesity for cardiovascular disease is thought to be mediated in part by the clustering of risk factors such as hypertension, hypercholesterolemia, and diabetes mellitus. 8 However, the relationship of obesity and weight gain in adult years to vascular disease is complex, that is, obesity has not been associated with poor outcomes in all patient populations with or at high risk for vascular disease. 9 In fact, among patients with known cardiac disease, an "obesity paradox," that is, a paradoxical decrease in morbidity and mortality with increasing body mass index (BMI), has been described. 10 It is also noteworthy that although a few data on the association of obesity with all-cause mortality after a recent stroke exist, 11, 12 data linking recent ischemic stroke with recurrent vascular risk are scarce. 13 For neurologists and stroke physicians who are generally involved in stroke prevention after the occurrence of a prior cerebrovascular event, knowledge about the role that a patient's weight status has on future prognosis could be insightful and provide even greater impetus to advocate for weight loss in obese patients.
The objective of this study was to evaluate whether baseline obesity is independently associated with recurrent vascular risk after stroke.
Methods
We reviewed data from the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS, ClinicalTrials.gov number NCT00153062). 14 The methods and main results of this trial have previously been reported. 14 -16 Briefly, from September 2003 to July 2006, PRoFESS enrolled 20 332 patients from 695 centers in 35 countries who recently had an ischemic stroke. Patients aged Ն55 years, or those aged 50 to 54 years with at least 2 additional vascular risk factors, who experienced an ischemic stroke Ͻ120 days before randomization and whose condition was stable participated in the study. 14 Ischemic stroke was defined as a new focal neurological deficit of cardiovascular origin persisting for Ͼ24 hours, but patients whose symptoms persisted for Ͻ24 hours could be included if they had evidence of a recent ischemic stroke on CT or MRI. Patients were excluded if they had a primary hemorrhagic stroke, severe disability after the qualifying stroke, contraindications to 1 of the study antiplatelet agents, or other factors making them unsuitable for randomization. 14 The trial used a 2-by-2 factorial design to compare 4 regimens: a combination of acetylsalicylic acid (aspirin) and extended-release dipyridamole as compared with clopidogrel and telmisartan as compared with placebo. 14 Patients were evaluated at the time of hospital discharge or in a clinic visit at 1 week and then at 1, 3, and 6 months and every 6 months thereafter. The minimum expected follow-up was 18 months. Interim telephone calls were scheduled halfway between clinic visits.
Average patient follow-up was 2.5 years. The primary outcome was first recurrence of stroke of any type. A central committee blindly adjudicated the primary outcome and the first of the secondary outcomes. The trial was approved by the ethics committee or Institutional Review Board at each national or local site, and all participants provided written informed consent. 14 
Statistical Analyses
Because no difference in efficacy was discerned between any of the treatment arms in PRoFESS, all patients were included in this analysis. 15, 16 BMI at baseline was calculated as weight in kilograms divided by square of height in meters. Expert consensus guidelines indicate that BMI is reliable and valid for identifying individuals at increased risk for morbidity due to obesity, particularly because other methods of measuring body fat may be impractical for routine use. 17 Waist circumference, differentially assessed at the midpoint between the lowest rib and the iliac crest, the umbilicus, or the minimum or maximum waist perimeter, is not widely used in routine clinical practice. 17 For the purpose of this analysis, PRoFESS subjects were divided into 3 groups based on recognized BMI categories of general adiposity. 17 : (1) individuals with BMI Ն30 kg/m 2 ϭClass I obesity; (2) individuals with BMI Ն25 kg/ m 2 ϭoverweight; and (3) individuals with BMI Ͻ25 kg/m 2 ϭlean. The lowest BMI category was the referent group for purposes of comparison. Baseline demographic and clinical covariates to be examined were preselected based on prior studies of factors that influence the occurrence of recurrent stroke. 18 Stepwise Cox proportional hazard models were used to estimate the risk of primary outcome, which was time to recurrent stroke. A secondary outcome of time to the first stroke, myocardial infarction, or vascular death was also evaluated. Patients not having these events were censored at the date of nonvascular death, last follow-up examination, or last contact. Adjustments for baseline characteristics were made by forcing the following prespecified covariates into the stepwise model: age, sex, history of prior stroke (before qualifying stroke), history of diabetes, history of myocardial infarction, average seated blood pressure over the trial, history of hypertension, and selecting other covariates with a probability value Յ0.10. For subjects of Asian race (including Chinese, Japanese, and Malays), we followed World Health Organization international classification recommendations, 19 that is, the cutoff BMI values were selected as Ն23 kg/m 2 for overweight and Ն27.5 kg/m 2 for obesity. We excluded South Asians primarily born on the Indian subcontinent from this latter BMI classification. See online supplemental material for additional methodology (http://stroke.ahajournals.org). A probability value of Յ0.05 was considered statistically significant. Analyses were carried out with SAS statistical software Version 8.2.
Results
Of 20 332 subjects enrolled in PRoFESS, BMI measurements were unavailable in 86 subjects, leaving 20 246 (99.6%) subjects for this analysis. Among those with complete data, mean age was 66.1Ϯ8.6 years, 36% were women, and 4805 (24%) were obese. The distribution of BMI and waist circumference in the overall cohort, and by sex, is presented in Supplemental Table I .
Overall, baseline demographic and clinical characteristics are shown in Table 1 . Compared with the lean and overweight groups, obese patients were slightly younger and had a higher (by Ն5 percentage points) proportion of women, persons with medical histories of hypertension, diabetes, hyperlipidemia, and individuals taking antihypertensive drugs. On the other hand, the obese category had fewer Asians, current smokers, and large vessel atherosclerotic strokes at baseline. Of note, there were no differences in history of previous stroke or transient ischemic attack (ie, before the trial-qualifying stroke) among BMI groups and despite the aforementioned higher frequency of hypertension/antihypertensive drug use, baseline median blood pressure levels were comparable across BMI groups. Figure 1 shows the unadjusted cumulative probability of the primary outcome of first recurrent stroke according to BMI category. First recurrent stroke occurred in 600 lean patients (9.06%), 778 overweight patients (8.82%), and 427 obese patients (8.89%). Figure 2 shows the unadjusted cumulative probability of the secondary outcome of first major vascular event after a recent ischemic stroke. The secondary outcome occurred in 958 patients (14.47%) in the lean category, 1081 patients (12.25%) in the overweight category, and 612 patients (12.74%) in the obese category. Occurrence of a first major vascular event after ischemic stroke was higher in the lean BMI category compared with the overweight and obese categories. Times to event results for the primary and secondary end points are provided in Table 2 . None of the interactions between BMI and major demographic and clinical characteristics were significant ( Table 2) . Analyses of the effect of obesity on recurrent vascular risk in a stratified analysis did not suggest any significant confounding by index stroke subtype (Supplemental Tables II and III) . Abdominal obesity was not significantly linked to either the primary or secondary outcome (data not shown).
Discussion
In this analysis of Ͼ20 000 subjects with recent ischemic stroke, we found that approximately one fourth were obese at baseline but that presence of baseline obesity was not an independent predictor of recurrent stroke risk over a 2.5-year follow-up period. A post hoc analysis of another secondary stroke prevention trial did find an association between obesity and risk of stroke recurrence, but this trial comprised approximately 1700 black subjects, and its results may not necessarily be generalizable to the broader population of patients with ischemic stroke. 13 There are several potential explanations for the lack of association between body habitus and recurrent stroke risk in our study. First, most of the epidemiological studies showing that obesity is an independent risk factor for stroke incidence and mortality were done in the general population without illness. 8 As such, it is conceivable that obesity itself may somehow exert a differential pathophysiological impact on the risk of primary versus secondary stroke, although mechanistically it is unclear how this would work. Second, the follow-up period in our study may have been an insufficient time period to find an effect of obesity on recurrent stroke risk, especially because many of the population-based studies for primary stroke went on for at least 5 years, oftentimes much longer. 8 Third, it could be that although primary strokes are more frequent in obese patients, thus putting these patients at higher risk for recurrence, the type of primary strokes associated with obesity may carry a more favorable prognosis than other stroke types. So, for instance, although we adjusted for index stroke mechanism in our multivariable analyses, it must be noted that obese patients were more likely to have index strokes due to small vessel disease, whereas lean patients were more likely to have index strokes due to large vessel atherosclerosis, a potent predictor of stroke recurrence. A fourth and perhaps the most plausible explanation may be that once a stroke has occurred, the implementation of several vascular risk reduction therapies may mitigate the avenues through which obesity may foster its deleterious effects. Indeed, we observed in our data that obese patients had more vascular risk factors at baseline compared with their leaner counterparts, yet control of the premier modifiable risk for stroke, hypertension, was comparable across BMI groups, probably due to the much higher rate of antihypertensive agent use noted in the obese category.
In contrast to the null results for the primary outcome, the results for the conflated secondary outcome showed that obese (and overweight) patients with ischemic stroke were at significantly lower overall vascular risk, and analysis of BMI as a continuous variable also showed that higher BMI was independently linked to lesser risk of the secondary outcome. This finding is in accordance with that observed in prospective registry studies in Greece and Denmark, which indicated that obese and overweight patients with first-time stroke had significantly fewer early and long-term all-cause mortality rates compared with those with normal BMI. 11, 12 All these studies strongly support the notion of an "obesity paradox," but our study further indicates that such a paradox is possibly driven by cardiovascular and not cerebrovascular underpinnings or that ischemic stroke is too heterogeneous a condition to properly evaluate the relationship between symptomatic vascular disease and obesity. Analyses of various patients with established cardiac disease have shown this paradox including patients with stable coronary artery disease, congestive heart failure, and those undergoing percutaneous coronary intervention. 10 Different mechanisms have been proposed to explain this paradox, including a higher percentage of high-risk coronary anatomy in normal-weight patients and more favorable hemodynamics of obesity-related hypertension as well as the fact that obese patients display a readily identifiable high cardiovascular risk phenotype that may lead to their receiving or seeking earlier/more aggressive treatment, thereby changing the natural history of their disease when compared with lean patients. 10 However, there is also a Figure 1 . Cumulative probability of first recurrent stroke (primary outcome) by body mass index category (lean, overweight, obese). possibility that recurrent risk analyses such as this are prone to bias that may lead to paradoxical results, 20 but it is not clear why in this study it would apply only to the composite outcome and not the stroke end point alone.
The majority of scientific evidence supports a role for obesity in the pathogenesis and progression of vascular disease. Furthermore, expert consensus guidelines recommend weight loss for overweight and obese patients for the primary prevention of stroke, 21 and these recommendations also have been extended to overweight and obese patients with established cerebrovascular disease. 18 However, given long-term data showing that weight loss in overweight and obesity may be associated with increased mortality, 10 evidence from many cardiac studies showing a better prognosis with a higher BMI, 10 data from our study indicating that obese patients with stroke are not necessarily at higher recurrent stroke risk than their leaner counterparts but may actually be at lower overall vascular risk, and no data demonstrating that weight reduction will reduce stroke recurrence, a fundamental clinical question going forward is whether weight loss should be routinely recommended as a therapeutic goal in overweight and obese patients with symptomatic vascular disease. 22 Further research is certainly needed, especially in the form of prospective randomized clinical outcome trials. In the meantime, most prevailing data support the vascular protective benefit of goal-directed weight reduction due to its favorable influence on blood pressure, serum glucose values, serum lipids, and physical endurance. 10 Some studies have suggested that abdominal adiposity, rather than general adiposity, is more related to stroke risk. 23 Although seen as impractical and possibly unreliable in routine clinical practice, 17 we also assessed the impact of baseline abdominal obesity on vascular outcome after stroke in an exploratory analysis but did not find a significant relationship with either the recurrent stroke or composite vascular end points. The precise reasons for this discrepancy between the effects of obesity measured by BMI as opposed to waist circumference are unclear but may lie in what the various indices of obesity purportedly measure. BMI is generally viewed as quantifying total body fat as well as lean mass, whereas the waist circumference indices only abdominal adiposity. Of note, other studies of patients with established vascular disease have also found high BMI to be protective but increased waist circumference to be associated with neutral risk. 24, 25 This study has limitations. Because this was a post hoc analysis of a clinical trial with specific inclusion and exclusion criteria (although none for weight or BMI, which may have biased the results), the findings may have been influenced by Lean (BMI Ͻ25 kg/m 2 non-Asian, BMI Ͻ23 kg/m 2 Asian), obese (BMI Ն30 kg/m 2 non-Asian, BMI Ն27.5 kg/m 2 Asian). BMI indicates body mass index; CI, confidence interval. *Stroke-only outcome adjusted for age, sex, previous stoke, diabetes, myocardial infarction, baseline systolic blood pressure, hypertension, qualifying stroke-small vessel disease, qualifying stroke-cardioembolic, current smoking status, baseline National Institutes of Health Stroke Scale score, previous transient ischemic attack. Conflated vascular outcome adjusted for age, sex, previous stoke, diabetes, myocardial infarction, baseline systolic blood pressure, hypertension, qualifying stroke-small vessel disease, qualifying stroke-cardioembolic, hyperlipidemia, coronary artery disease, current smoking status, antihypertensive medication at baseline, baseline National Institutes of Health Stroke Scale score, previous transient ischemic attack, Asian ethnicity.
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unknown confounders. As a result, the conclusions should be considered hypothesis-generating. Furthermore, we compared outcomes among overweight and obese versus lean patients with ischemic stroke but did not specifically explore information about those within the lean category, some of whom may have been unhealthily lean due to unintentional weight loss, which could lead to an overestimation of the poor prognosis of the lean weight reference group. 26 Also, baseline BMI and waist circumference were not systematically validated throughout the trial, and because the mechanistic effect of obesity is likely through atherosclerosis, it would be expected that the strongest association between baseline BMI versus stroke outcome would be with atherosclerotic stroke outcome, but stroke outcome subtype was not rigorously evaluated within PRoFESS. Strengths of the study include its large size, prospective data collection, rigorous study procedures, and recruitment of subjects of various races from several countries.
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SUPPLEMENTARY MATERIAL

METHODS
For estimation of the risk of the primary outcome, additional covariates in the model were current smoking status, baseline NIHSS, previous TIA, and indicator variables for qualifying stroke sub-types of cardioembolic, and small vessel disease. For estimation of the risk of the secondary outcome, additional covariates included in the model were: current smoking status, baseline NIHSS, previous TIA, history of coronary artery disease, history of hyperlipidemia, use of antihypertensive medicine at baseline, ethnicity (Asian/ non-Asian) and indicator variables for qualifying stroke sub-types of cardioembolic, and small vessel disease. Tests for interaction for pre-specified baseline features including age, sex, race, ethnicity, history of diabetes, and history of hypertension were also performed. To further explore any potential residual confounding influences we also performed an analysis of the effect of obesity on recurrent vascular risk stratifying by index stroke subtype. We also conducted an additional analysis using a
Cox model with BMI as a continuous predictor (along with sex and ethnicity) in the overall cohort and across baseline stroke subtypes. Since PRoFESS also collected data on waist circumference we analyzed in exploratory fashion the unadjusted effect of abdominal obesity on outcome using a definition of abdominal obesity of waist circumference greater than 35 inches for women and above 40 inches for men.
RESULTS
The results of the continuous BMI analysis (supplementary 
